相关实验视频

Updated: May 5, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

在高风险的皮肤冠状动脉干预后,左心室功能和结果的变化,使用Impella引导的血液动力学支持

Serdar Farhan¹, Michael Freilich², Gennaro Giustino¹

¹The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

Frontiers in cardiovascular medicine

|July 22, 2024

概括

通过Impella支持的高风险穿皮冠状动脉干预 (HRPCI) 可以改善超过40%的患者的左心室喷射率 (LVEF). 然而,在本研究中,LVEF的改善并没有显著改变1年心血管不良结果.

科学领域:

心脏病学心脏病学
干预心脏病学干预心脏病学
心脏外科手术心脏外科手术

背景情况:

高风险穿皮冠状动脉干预 (HRPCI) 为冠状动脉疾病和左心室喷射率 (LVEF) 减少的患者提供一种治疗选择.
HRPCI对LVEF改善和随后的临床结果的影响仍然不完全理解.

研究的目的:

确定Impella引导HRPCI后LVEF改善的发生率和预测因素.
为了比较介入后LVEF改善的和没有LVEF改善的患者之间的临床结果.

主要方法:

从单一中心注册表中对连续接受Impella引导HRPCI的患者进行了回顾性分析.
在干预后≥30天,LVEF的改善被定义为≥10%的绝对增加.
主要结局是所有死因,心肌梗塞或1年内目标血管再血管化的综合结果.

主要成果:

超过40%的患者 (70/161) 实现了LVEF改善 (25.1%至33.3%).
与没有LVEF改善相关的因素包括先前的心肌梗塞,心电图上的Q波和较高的SYNTAX得分.
在患有和没有LVEF改善的患者中,一年内不良心血管事件的发生率相似 (34.9%和38.3%).

结论:

在接受Impella引导HRPCI的患者中,显著比例的LVEF可以得到改善.
史上的心脏病发作,心电图Q波和较高的SYNTAX分数与缺乏LVEF改善有关.
需要进一步的前性研究来澄清HRPCI后LVEF改善的长期临床意义.

关键词:

伊姆佩拉 (Impella) 是一种.在SYNTAX中,分数是SYNTAX的分数.高风险的穿皮冠状动脉干预.左心室喷射分数的部分.机械循环装置是指机械循环装置.

更多相关视频

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

相关概念视频

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...